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ABSTRACT
Cytogenetics has an important impact on the prognosis of patients undergoing allogeneic hematopoietic stem
cell transplantation (HSCT) for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).
However, it is unclear whether currently accepted cytogenetic risk groups, which were established for patients
treated mostly with standard therapy, are optimally discriminating for patients undergoing HSCT. Also, the
impact of cytogenetics in the growing population of patients with therapy-related disease has not been
completely elucidated. In this study, we retrospectively analyzed data on 556 patients with AML or MDS
transplanted at our institution. We examined, in multivariate analyses, the contribution of cytogenetics to
survival, relapse, and nonrelapse mortality for the 476 patients with de novo disease. We used these results to
establish an optimal cytogenetic grouping scheme. We then applied this grouping scheme to the 80 patients
with therapy-related disease. Our proposed 3-group cytogenetic classification outperformed the established
grouping schemes for both de novo and therapy-related disease. When classified by this new scheme,
cytogenetics was the strongest prognostic factor for overall survival in our cohort, through its impact on the
risk of relapse (and not on nonrelapse mortality). After accounting for cytogenetics, patients with therapy-
related AML or MDS had an equivalent outcome to those with de novo disease. This study demonstrates the
impact of cytogenetics on the risk of relapse and death for patients with both de novo and therapy-related
disease undergoing transplantation; it also emphasizes the necessity of using cytogenetics to stratify patients
entering clinical trials, and provides a system for doing so, which can be validated in a multi-institutional
database.
© 2007 American Society for Blood and Marrow Transplantation
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Numerous studies have demonstrated the impor-
ance of cytogenetic abnormalities for the prognosis of
atients with acute myelogenous leukemia (AML)
1-3] or myelodysplastic syndrome (MDS) [4, 5]
reated with standard therapy. It has also been estab-
ished that cytogenetics is prognostically signiﬁcant
fter allogeneic hematopoietic stem cell transplanta-
ion (HSCT) [6-10]. However, the existing cytoge-
etic risk grouping schemes may not be optimal for
atients undergoing HSCT. Because the efﬁcacy of tSCT relies in part on immune mechanisms, diseases
ith a given karyotype might behave differently after
SCT than they would after chemotherapy or with
upportive care alone. Therefore, cytogenetic risk
roups that are based on series of patients treated with
onventional chemotherapy may not apply to trans-
lanted patients. Four cooperative groups have pro-
osed cytogenetic grouping schemes for AML, based
n independent series of patients [11-14]. Most of the
atients on whom these schemes are based were
reated with chemotherapy alone. In the case of MDS,
here is only 1 widely accepted prognostic scheme, the
655
I
T
t
a
a
b
e
a
r
a
s
c
m
t
g
d
n
t
o
v
1
s
o
d
k
p
2
b
n
t
p
d
p
H
d
d
e
3
i
f
r
p
i
g
M
u
s
e
e
t
d
d
d
t
a
M
P
u
w
F
1
W
a
w
l
“
s
t
d
t
y
E
w
w
l
A
d
(
t
o
r
t
r
w
w
t
f
w
t
C
w
c
t
[
d
m
c
f
j
f
T
(
[
f
P. Armand et al.656nternational Prognostic Scoring System (IPSS) [5].
his scheme was based on a large series of patients
reated primarily with supportive care. It is likely that
nalyzing a series of patients treated uniformly with
llogeneic transplantation would result in a new
reakdown of cytogenetic risk groups for both dis-
ases. A new grouping scheme would be useful in
ssessing the impact of cytogenetics on the risk of
elapse and the risk of nonrelapse mortality (NRM)
fter HSCT. Moreover, such a scheme would allow
tratiﬁcation of patients with AML or MDS entering
linical trials in transplantation, which is not yet com-
only done.
The inﬂuence of cytogenetics in patients with
herapy-related AML or MDS (tAML/MDS) under-
oing HSCT is also unclear [15-18]. Therapy-related
isease is assuming a growing importance, given the
umber of patients treated with autologous stem cell
ransplantation, a procedure with a documented risk
f MDS/AML ranging from 1% to 24% [19]. Con-
ersely, therapy-related AML represented as many as
3% of unselected consecutive AML cases in 1 large
eries [20]. Patients with tAML/MDS have an inferior
utcome in general compared to patients with de novo
isease [21-23]. However, those patients often harbor
aryoptypic abnormalities that confer an adverse
rognosis in the setting of de novo AML/MDS [20,
4-27]. This could contribute to their inferior survival
ecause, even when AML is therapy-related, cytoge-
etics are of prognostic signiﬁcance when patients are
reated with chemotherapy [21, 23, 26]. Given the
oor outcome with chemotherapy for therapy-related
isease, allogeneic HSCT is often performed if the
atient is a candidate and a suitable donor is available.
owever, there are no prospective trials to guide this
ecision. Published retrospective series of patients un-
ergoing HSCT for tAML/MDS vary widely in their
stimates of long-term survival, ranging from 0% to
0% [15-18, 28, 29]. To choose the best treatment for
ndividual patients with tAML/MDS, it would be use-
ul to know the outcome of HSCT for each cytogenetic
isk group, and to better understand the contribution of
rior therapy to prognosis after transplantation.
We undertook the present study with the follow-
ng aims: (1) to establish an optimal cytogenetic risk
rouping scheme for patients with de novo AML or
DS; (2) to characterize the impact of cytogenetics
sing this new scheme; (3) to determine whether this
cheme can stratify patients with therapy-related dis-
ase into prognostically distinct subgroups; and (4) to
xamine the independent prognostic impact of prior
herapy after cytogenetics are taken into account. To
o this, we retrospectively studied 476 patients with
e novo disease and 80 patients with therapy-related
isease who underwent allogeneic HSCT at our insti-
ution, and analyzed their outcomes using multivari-
ble analysis. mETHODS
atients and Cytogenetics
We reviewed the medical records of 556 consec-
tive adult patients with AML or MDS who under-
ent allogeneic stem cell transplantation at the Dana-
arber Cancer Institute between September 1983 and
997, and at the combined Dana-Farber/Brigham and
omen’s Hospital transplant program between 1997
nd August 2005. We included patients with AML in
hom the clinical circumstances suggested that the
eukemia arose from MDS. We do not use the term
secondary AML” for those patients to avoid confu-
ion with therapy-related AML, and instead use the
erm “myelodysplastic AML” or “mAML.”
We classiﬁed patients as having therapy-related
isease if they had received alkylating chemotherapy,
opoisomerase-II inhibitor therapy, or radiotherapy 1
ear or more prior to their diagnosis of AML/MDS.
ighty patients met this criterion (the remaining 476
ere classiﬁed as having de novo disease). For patients
ith AML and a history of leukemogenic therapy, we
abeled the disease therapy-related myelodysplastic
ML if they had clinical evidence of MDS prior to the
iagnosis of AML, and as therapy-related AML
tAML) if not. We calculated the time from prior
herapy to diagnosis of tAML/MDS based on the date
f the ﬁrst leukemogenic treatment received.
Tumor cytogenetics at diagnosis (for patients in
emission) or at the time of transplantation (for pa-
ients with active disease) were extracted from the
ecords. Only standard karyotype banding techniques
ere used for most of the patients, and central review
as not required. Risk groups were assigned according
o the various published grouping schemes, with the
ollowing modiﬁcations: ﬁrst, patients with t(15;17)
ere classiﬁed as favorable under all schemes, even
hough those patients are not classiﬁed under the
ALGB or the EORTC/GIMEMA schemes; second,
e included patients with del(16q22) in the favorable
ategory if they had M4 AML subtype, as those pa-
ients can harbor an undetected CBF-MYH11 fusion
30, 31]; ﬁnally, “complex cytogenetics” was uniformly
eﬁned for all grouping schemes as 3 or more abnor-
alities. In the case of MDS, we followed the IPSS
ytogenetic classiﬁcation [5].
Institutional review board approval was obtained
rom the Ofﬁce for the Protection of Research Sub-
ects at Dana-Farber/Harvard Cancer Center to per-
orm this study.
ransplantation
Conditioning regimens were either myeloablative
mostly cyclophosphamide plus total body irradiation
TBI]) (n  424), or reduced intensity (mostly busul-
an plus ﬂudarabine) (n 132). Patients received bone
arrow (BM) (n  298), peripheral blood stem cells
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Cytogenetics for AML and MDS after HSCT 657PBSC) (n  247), or umbilical cord blood (UCB) (n 
1) grafts. Donors were matched related (n  293),
atched unrelated (n 199), or mismatched (n 64).
raft-versus-host disease (GVHD) prophylaxis regi-
ens included pharmacologic prophylaxis regimens
ased on a calcineurin inhibitor (n 235), those based
n the combination of calcineurin inhibitor and siroli-
us (n  138), and ex vivo T cell depletion (n  183).
tatistics
Two-sided Fisher’s exact test was used to compare
aseline cytogenetic characteristics. Overall survival
OS) and disease-free survival (DFS) were calculated
sing the Kaplan-Meier method. OS was deﬁned as
he time from stem cell infusion to death from any
ause. Patients who were alive or lost to follow-up
ere censored at the time last seen alive. DFS was
eﬁned as the time from stem cell infusion to relapse
r death from any cause. Patients who were alive
ithout relapse were censored at the time last seen
live and relapse-free. The log-rank test was used for
omparisons of Kaplan-Meier curves. Cumulative in-
idence curves for nonrelapse death and relapse with
r without death were constructed reﬂecting time to
elapse and time to nonrelapse death as competing
isks. The difference between cumulative incidence
urves in the presence of a competing risk was tested
sing the Gray method [32]. Potential prognostic fac-
ors for survival, DFS, relapse, and nonrelapse death
ere examined in the proportional hazards model as
ell as in the competing risks regression model [33].
nteraction terms including interaction with time were
xamined in the proportional hazards regression
odel. Proportional hazards assumption for each vari-
ble of interest was tested.
ESULTS
atient Characteristics and Cytogenetics
The baseline characteristics of the 476 patients
ith de novo disease and the 80 patients with therapy-
elated disease included in this study are shown in
able 1. The median age for the entire cohort was 45
ears. Median follow-up for survivors was 34 months
range, 6-246).
Among the patients with therapy-related disease,
ost had a primary diagnosis of lymphoma (35% had
on-Hodgkin’s lymphoma, 19% had Hodgkin’s lym-
homa). Almost all of the patients (95%) had received
rior alkylator therapy; 73% had received a topoisom-
rase II inhibitor, whereas 65% had received prior
adiation. Fifty-three percent of the patients had pre-
iously undergone autologous stem cell transplanta-
ion. The median time from ﬁrst leukemogenic ther-
py to diagnosis of AML/MDS was 7 years (range,
-25 years). pNinety-one percent of all patients had available
ytogenetic data, which are presented in Table 2. We
sed the MRC and IPSS grouping schemes as our
tarting points for AML and MDS, respectively.
hen classiﬁed according to these schemes, 27% of
able 1. Baseline Characteristics of the Patients
De Novo
Disease
Therapy-Related
Disease
Variable Number (%)* Number (%)*
umber of patients: 476 (100) 80 (100)
ge in years (median, range) 45 (17-71) 47 (21-66)
isease:
AML 308 (65) 21 (26)
MDS 74 (16) 42 (53)
RA, RARS, RCMD 39 (8) 20 (25)
RAEB 35 (7) 22 (28)
AML from MDS 94 (20) 17 (21)
ML/mAML stage:†
First CR 154 (38) 13 (34)
Second or higher CR 102 (25) 6 (16)
Active disease 146 (36) 19 (50)
raft
Bone marrow 260 (55) 38 (48)
Peripheral blood 207 (43) 40 (50)
Umbilical cord blood 9 (2) 2 (3)
atch
MRD 262 (55) 31 (39)
MUD 159 (33) 40 (50)
Mismatched 55 (12) 9 (11)
Mismatched related 13 (3) 2 (3)
Mismatched unrelated 42 (9) 7 (9)
onditioning
Myeloablative 381 (80) 43 (54)
Reduced intensity 95 (20) 37 (46)
VHD prophylaxis
CnI / Mtx or steroids 203 (43) 32 (40)
CnI  Siro / Mtx 114 (24) 24 (30)
TCD 159 (33) 24 (30)
ender recipient/donor
Male/female 107 (22) 17 (21)
Female/male 110 (23) 25 (31)
Female/female 114 (24) 19 (24)
Male/male 140 (29) 18 (23)
ecipient CMV seropositive 208 (44) 28 (35)
onor CMV seropositive 160 (34) 29 (36)
ear of transplantation
1983-1989 22 (5) 3 (4)
1990-1999 155 (33) 24 (30)
2000-2005 299 (63) 53 (66)
A indicates refractory anemia; RARS, refractory anemia with
ringed sideroblasts; RCMD, refractory cytopenia with multilin-
eage dysplasia; RAEB, refractory anemia with excess blasts; CR,
complete remission; MRD, matched related donor; MUD,
matched unrelated donor; GVHD, graft-versus-host disease;
CnI, calcineurin inhibitor (cyclosporine or tacrolimus); Mtx,
methotrexate; Siro, sirolimus; TCD, T cell depletion; and
CMV, cytomegalovirus; AML, acute myelogenous leukemia;
MDS, myelodysplastic syndromes.
Percentages may not add to 100 because of rounding.
Percentage for this category refers to the percent of AML/mAML
patients, not to the percent of total patients.atients with de novo disease had favorable cytogenet-
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P. Armand et al.658cs, versus 11% of patients with therapy-related dis-
ase (p  .003); 47% of patients with de novo disease
ad intermediate cytogenetics, compared to 21% of
atients with therapy-related disease (p  .0001); and
7% of patients with de novo disease had adverse
ytogenetics, compared to 60% of patients with ther-
py-related disease (p  .0001).
There was a signiﬁcant association between cyto-
enetic risk group and both age and remission status
n our series. Twenty-seven percent of the patients age
0 and over had adverse cytogenetics, compared to
8% of the patients under age 40 (p  .043); 6% of
he patients 40 and over had favorable cytogenetics
ompared to 13% of patients under age 40 (p  .007).
mong patients with acute leukemia, 25% of patients
ith early-stage disease had adverse cytogenetics,
ompared to 11% of patients beyond CR1 (p 
0002); 2% of patients with early-stage disease had
avorable cytogenetics, compared to 15% of patients
able 2. Cytogenetics
Variable De Novo Disease Numbe
ML cytogenetics†
Number of patients 308 (100)
Favorable 45 (15)
t(8;21) 5 (5)
inv(16) or t(16;16) 18 (6)
t(15;17) 12 (4)
Intermediate 186 (60)
Normal 119 (39)
8 17 (6)
del(9q) 4 (1)
Abnormality of 11q23 2 (4)
t(9;22) 4 (1)
t(6;9) 4 (1)
Other 26 (8)
Adverse 42 (14)
5, del(5q), or 7 16 (5)
Abnormal 3q 1 (0)
Complex 25 (8)
Not obtained/not available 35 (11)
DS and mAML cytogenetics‡
Number of patients 168 (100)
Favorable MDS 82 (49)
5q- 2 (1)
20q- 1 (1)
Y- 0 (0)
Normal 79 (47)
Intermediate MDS 37 (22)
All others 37 (22)
Adverse MDS 38 (23)
Abnormal 7 11 (7)
Complex 27 (16)
Not obtained/not available 11 (7)
ML, indicates acute myelogenous leukemia; MDS, myelodysplast
Percentages may not add to 100 because of rounding.
Classiﬁed according to MRC grouping scheme.
Classiﬁed according to the IPSS grouping scheme.eyond CR1 (p  .0001). 1rognostic Factors for Overall Survival (OS)
n De Novo AML and MDS
We ﬁrst considered the group of 476 patients with
e novo disease. We assigned patients to cytogenetic
isk groups using the MRC scheme for AML and the
PSS scheme for MDS or AML arising from MDS
mAML). Using proportional hazards modeling in-
luding all of the variables from Table 1, we found the
ollowing to be signiﬁcant prognostic factors for OS in
his population: age, cytogenetic risk group, disease
ype, disease stage at transplant, GVHD prophylaxis
egimen, and HLA match (data not shown). In this
odel, the hazard ratio (HR) for patients with favor-
ble cytogenetics (compared to those with intermedi-
te cytogenetics) was 0.5 (p  .0001); the HR for
dverse cytogenetics compared to intermediate was
.7 (p  .003). Of note, the HR for patients whose
ytogenetics was not obtainable or not available was
Therapy-Related Disease Number (%)* P value
21 (100)
2 (10) .8
0 (0)
0 (0)
2 (10)
11 (52) .5
5 (24)
0 (0)
0 (0)
2 (10)
0 (0)
0 (0)
4 (19)
7 (33) .024
3 (14)
0 (0)
4 (19)
1 (5) .1
59 (100)
7 (12) <.0001
0 (0)
0 (0)
0 (0)
7 (12)
6 (10) .12
6 (10)
41 (69) <.0001
16 (27)
25 (42)
5 (8) .6
romes.r (%)*
ic synd.1 (p  .6) in comparison to the entire group with
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Cytogenetics for AML and MDS after HSCT 659vailable cytogenetics. Thus, the group of patients
ith available cytogenetics does not appear to be a
iased subsample of the entire study population. The
esults conﬁrm the importance of cytogenetics in
ransplantation outcome; they remained essentially
nchanged whether we used the MRC [11], CALGB
12], SWOG/ECOG [13], or EORTC/GIMEMA
14] schemes for classiﬁcation of AML cytogenetics.
ew Cytogenetic Risk Groups for
e Novo Patients
We repeated the multivariate analysis considering
nly the 308 patients with de novo AML, separating
ytogenetics into individual abnormalities. We only
onsidered abnormalities found in 3 patients. Ab-
ormalities found in 3 patients, and classiﬁed as
ntermediate under the MRC grouping scheme, were
umped into an “all others” category. We added to the
odel the prognostic factors identiﬁed above. The
esults, shown in Table 3 (top), suggest the existence
f 3 distinct risk groups for AML. The same analysis,
erformed for the 168 patients with de novo MDS or
AML, suggest the existence of 2 distinct groups
Table 3, bottom). An analysis limited to the patients
ith MDS yielded the same grouping scheme as 1
ombining patients with MDS and mAML. When we
xamined which of the existing grouping schemes (in-
luding existing AML and MDS schemes, and our
ew groups for AML and MDS) could best stratify the
able 3. Risk Group Determination for De Novo Patients
HR P Risk Group
ML cytogenetic abnormality
(8;21) alone 0.2 .035 Favorable
nv(16)/t(16;16)/del(16q22)
with M4 0.2 .002
(15;17) 0.3 .025
el(9q) 0.7 .6 Standard
ll others 0.9 .9
ormal (reference group) 1.0
(8;21)  del(9q) or complex 1.1 .9
risomy 8 1.1 .9
bnormal 5 or 7 1.1 .8
bnormal 11q23 1.4 .4
omplex 2.6 .0005 Adverse
(9;22) 3.6 .024
(6;9) 11.6 <.0001
DS/mAML cytogenetic
abnormality
bnormal 3q 0.7 .7 Standard
ormal (reference group) 1.0
bnormal 5 1.2 .9
risomy 8 1.2 .7
ll others 1.4 .1
bnormal 7 2.2 .050 Adverse
omplex 3.4 <.0001
R indicates hazard ratio; AML, acute myelogenous leukemia;
tMDS, myelodysplastic syndromes.4 patients with mAML in multivariate analysis, our
ew MDS grouping scheme was the most discrimi-
ating (p  .002).
Based on the above results, there are 7 potentially
istinct disease/cytogenetic categories for transplanted
atients: 3 for AML, 2 for MDS, and 2 for mAML. To
urther simplify our system, we considered each of the
groups in turn, and used it as the reference group in
multivariate analysis, with the 6 other groups as
omparisons. The models (not shown) suggest the
xistence of 3 distinct overall risk groups, summarized
n Table 4. Within each group, there was no statisti-
ally signiﬁcant difference in survival between any of
he group members. Between any members of distinct
roups, there was a statistically signiﬁcant difference
n survival (p  .05).
mpact of Cytogenetics in De Novo Disease Using
ew Classification
Figure 1 shows the outcomes of all patients with
e novo disease (AML, MDS, and mAML) when cat-
gorized by this scheme. OS is shown in Figure 1A;
-year OS for the favorable, standard-risk, and adverse
roups were 70% (95% conﬁdence interval [CI], 56-
5), 33% (CI, 27-39), and 8% (CI, 0-16), respectively.
FS is shown in Figure 1B; 5-year DFS for the fa-
orable, standard-risk, and adverse groups were 64%
CI, 48-80), 32% (CI, 26-37), and 7% (CI, 0-15),
espectively. Cumulative incidence of relapse (CIR) is
hown in Figure 1C. In competing risk regression
nalyses [33] for CIR using our new risk groups and
able 4. Summary of New Grouping Scheme
Group AML
MDS or AML arising
from MDS
avorable t(8;21) alone
inv(16)/t(16;16)/
del(16q22) with
M4
t(15;17)
tandard-risk Normal Normal
del(9q) Abnormal 3q
t(8;21)  del(9q) or
complex
Abnormal 5
Trisomy 8
Trisomy 8 All others
Abnormal 5 or 7
Abnormal 11q23
All others
dverse Complex Abnormal 7
t(9;22) Complex
t(6;9)
atients with AML and abnormal 3q, as well as patients with MDS
and 5q-, 20q-, or Y- are not classiﬁed in this analysis, as too few
patients with those abnormalities were present in our cohort to
assign to a risk group.
ML, acute myelogenous leukemia; MDS, myelodysplastic syn-
dromes.he other variables from Table 1, cytogenetics signif-
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P. Armand et al.660cantly affected the risk of relapse, with HR 2.0 (p
002) for adverse risk, and HR  0.3 (p  .006) for
avorable risk, compared to standard risk (Table 5). In
ontrast, cytogenetics did not signiﬁcantly affect
RM (Figure 1D), with HR  1.6 (p  .07) for
dverse, and HR  0.6 (p  .2) for favorable (com-
ared to standard risk) in competing risks regression
nalysis (Table 5).
This grouping scheme retained statistically signif-
cant prognostic importance if the analysis was con-
ned to any 1 of the following disease groups: AML in
R1 or beyond CR1 (Figure 2), MDS, or mAML. It
lso applied equally well to patients receiving T cell-
epleted grafts and to those receiving a T cell replete
ne (not shown).
rognosis in Therapy-Related Disease
We built proportional hazards model for the 80
atients with therapy-related disease (AML, MDS, or
AML), using cytogenetics grouped according to our
ew system, as well as all of the covariates from Table
. We emphasize that those 80 patients were not
ncluded in the derivation of the grouping scheme. In
his model, the HR for adverse cytogenetics (com-
ared to standard risk) was 2.6 (p  .046). Because
here were only 2 patients with therapy-related disease
igure 1. Survival, relapse, and nonrelapse mortality for all de nov
A) Overall survival, (B) disease-free survival, (C) cumulative incidend favorable cytogenetics (with 5-year survival of s00%), we could not draw meaningful statistical con-
lusions for this group. Although adverse cytogenet-
cs appeared to be associated with inferior survival
sing any of the previously established grouping
chemes, our new classiﬁcation was the only one
hat allowed statistically signiﬁcant stratiﬁcation.
igure 3 shows the outcomes of all patients with
herapy-related disease when categorized by this
cheme. OS is shown in Figure 3A; 5-year OS for
he favorable, standard-risk, and adverse groups
ere 100% (CI, not obtainable), 54% (CI, 34-73),
nd 13% (CI, 0-28), respectively. DFS) is shown in
igure 3B; 5-year DFS for the favorable, standard-
isk, and adverse groups were 100% (CI, not ob-
ainable), 51% (CI, 31-70), and 9% (CI, 0-20),
espectively.
Given that our classiﬁcation system was as ap-
licable to therapy-related disease as it was to de
ovo disease, we performed multivariate analyses
or OS on the entire cohort of 556 patients, includ-
ng both patients with de novo disease and those
ith therapy-related disease, using cytogenetics
grouped by our new system) and a term for prior
herapy (as well as all covariates from Table 1). The
esults are displayed in Table 6. Adverse cytogenet-
cs was associated with an HR of 2.4 compared to
nts, stratiﬁed by cytogenetics according to new grouping scheme.
relapse, (D) nonrelapse mortality.o patietandard risk (and of 9.4 when compared to favor-
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Cytogenetics for AML and MDS after HSCT 661ble), and favorable cytogenetics with an HR of 0.3
ompared to standard risk (all with P  .0001).
otably, prior therapy was not a signiﬁcant prog-
ostic factor for OS (HR  0.9, P  .5), or for DFS;
his was the also case if tAML and tMDS/mAML
ere considered individually. This held true when
sing any of the existing cytogenetic risk grouping
chemes. Using competing risk regression analysis
ccounting for cytogenetic risk group, we found no
igniﬁcant difference between de novo disease and
herapy-related disease for either incidence of re-
apse (for therapy-related disease compared to de
ovo, HR  0.8, P  .5) or NRM (HR  1.3, P 
3). In further multivariate analyses (not shown),
either the type of prior therapy received (alkylator
ersus topoisomerase II inhibitor versus radiother-
py), nor a prior history of autologous stem cell
ransplantation, nor the time between ﬁrst leuke-
ogenic therapy and diagnosis of tAML/MDS, sig-
able 5. Competing Risks Regression Analysis of Relapse and
onrelapse Mortality for All Patients with De Novo Disease, Using
ew Cytogenetic Risk Groups
Variable
HR for
relapse P
HR for
NRM P
ytogenetics
Standard-risk
(reference) 1.0 1.0
Favorable 0.3 .006 0.6 .2
Adverse 2.0 .002 1.6 .070
ge NS 1.03 .008
isease/stage
AML in CR1
(reference) 1.0 1.0
CR > 2 1.8 .009 1.7 .058
Active disease 2.6 <.0001 1.0 .9
RA/RARS/RCMD 0.4 .041 1.6 .3
RAEB 0.7 .4 1.3 .5
mAML in CR1 0.9 .7 1.6 .078
atch
MRD (reference) 1.0 1.0
MUD 0.8 .2 2.6 <.0001
Mismatched 0.7 .4 3.4 .0002
onditioning
Cy/TBI (reference) 1.0 1.0
Bu/Cy 1.3 .6 0.7 .7
Reduced intensity 2.7 .0005 0.1 <.0001
VHD prophylaxis
CnI / Mtx*
(reference) 1.0 1.0
CnI  Siro / Mtx 1.2 .4 0.3 .003
TCD 1.2 .5 0.9 .8
raft source (bone marrow versus peripheral blood versus cord
blood), CMV serostatus of donor and recipient (positive versus
negative or unknown), female-to-male transplant, and year of
transplant (in 10-year blocks) were not signiﬁcant in this
analysis.
R indicates hazard ratio; NRM, nonrelapse mortality; NS, non-
signiﬁcant; Cy, cyclophosphamide; TBI, total body irradiation;
Bu, busulfan; other abbreviations are explained in Table 1.iﬁcantly affected OS. tISCUSSION
Our results conﬁrm the critical prognostic role
f cytogenetics for patients with AML or MDS
ndergoing HSCT [6-10], even after controlling for
ther known prognostic factors. When grouped ac-
ording to our transplant-speciﬁc scheme, cytoge-
etic risk group carried the greatest prognostic
eight of any of the examined risk factors in our
ohort. Speciﬁcally, cytogenetic risk group was a
ore important determinant of outcome than dis-
ase type, conditioning regimen intensity, use of T
ell depletion or choice of pharmacologic regimen
or GVHD prophylaxis. Although 9% of the pa-
ients in our cohort did not have available cytoge-
etic information, their outcome was not different
rom that of the patients with available cytogenetics,
mplying the absence of a signiﬁcant selection bias
or cytogenetics. Naturally, because this study is a
etrospective analysis of patients selected for trans-
lantation, the results do not necessarily apply to
atients at the time of diagnosis; in particular, cy-
ogenetics [11, 12], prior MDS, and prior therapy
21, 26, 34] can both affect the rate of remission for
ML, which our data does not capture.
The major difference between our AML grouping
cheme and the existing AML schemes is the inclusion
f AML patients with abnormalities of chromosome 5
r 7 in the standard-risk group. Because the effect of
ytogenetics was primarily on the risk of relapse, and
ecause there was no apparent interaction between
onditioning regimen intensity and cytogenetic risk
roup, this suggests that those karyoptypic abnormal-
ties, although they appear to confer increased resis-
ance to standard chemotherapy, may be sensitive to
he immunologic effect of transplantation. It must be
oted that this conclusion is based on a small number
f patients, and will require validation in a larger
tudy.
Another important ﬁnding from our analysis is
hat prior therapy does not by itself constitute an
dverse prognostic factor after transplantation. This
onclusion can only be drawn after accounting for
ytogenetics, as patients with therapy-related disease
ore often harbor adverse karyotypic abnormalities
han their de novo counterparts (as they did in our
ohort). Our results can be considered in the context
f treatment decisions for patients with therapy-re-
ated disease. Unfortunately, there are no prospective
rials comparing consolidation chemotherapy to
SCT for this group of patients speciﬁcally. The
urvival of transplanted patients with tAML/MDS
n our series (5-year OS of 100%, 54% and 13% for
avorable, standard, and adverse cytogenetic risk,
espectively) compare very favorably with the pre-
iously reported survival of tAML/MDS patients
reated with standard therapy (5-year OS of 47%-
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P. Armand et al.6624% in the largest series of patients with therapy-
elated AML with favorable cytogenetics [35], and
-year OS of 0%-10% and 0%-5% in recent studies
f tAML/MDS patients with standard and adverse
ytogenetics [23, 25], respectively). This compari-
on lends some measure of support, albeit through
etrospective data, to the use of allogeneic trans-
lantation in this setting.
Validation of our classiﬁcation scheme on an in-
ependent series of transplant patients will be critical
n 3 ways. First, this study is a retrospective study,
hich spans a large time interval; moreover, the
ost recently transplanted patients do not have
xtended follow-up. Therefore, our classiﬁcation
cheme should be viewed as tentative until it can be
alidated in a larger patient series. Second, such vali-
ation will help in classifying patients with AML and
bnormal 3q, or with MDS and 5q-, 20q-, or Y-,
hich we were unable to do because of insufﬁcient
epresentation; ﬁnally, a larger cohort may allow ﬁner
ubgroupings (eg, separating “abnormalities of 5 or 7”
nto 5-, 5q-, 7-, and 7q-). Further in the future, risk
rouping schemes will likely be reﬁned by improve-
ents in cytogenetic techniques; by the use of ﬂuo-
igure 2. Overall survival of patients with AML, stratiﬁed by cytoge
B) patients with AML beyond CR1.
igure 3. Survival of all patients with therapy-related disease, stratiﬁ
B) disease-free survival. Note that the favorable group included only 2 paescence in situ hybridization and polymerase chain
eaction to detect unapparent cytogenetic abnormali-
ies and molecular defects, respectively; and perhaps
ore importantly, by testing for molecular abnormal-
ties, such as FLT-3, KIT, or NPM1 mutations, or
AALC expression [6-39], that are now recognized as
aving a signiﬁcant prognostic role in the outcome of
atients with AML.
In summary, we have conﬁrmed a powerful prog-
ostic role for cytogenetics in the outcome of patients
ndergoing allogeneic HSCT, through its inﬂuence
n the risk of relapse. We propose a new cytogenetic
isk grouping scheme speciﬁcally applicable to this
atient population, which we hope to validate in a
ulti-institution database. This scheme applies to pa-
ients regardless of disease, stage, or prior history of
eukemogenic therapy. Prior therapy by itself does not
ppear to be an adverse risk factor after transplanta-
ion, once cytogenetic risk group is taken into ac-
ount. Our results strongly underscore the necessity
f stratifying patients by cytogenetics in clinical trials,
hich is not currently routinely done. Once validated,
ur grouping system could provide a basis for such
tratiﬁcation.
ccording to new grouping scheme. (A) Patients with AML in CR1,
ytogenetics according to new grouping scheme. (A) Overall survival,netics aed by c
tients.
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